The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial

Key Points

• The study aimed to determine if a gene expression profile can predict SLN positivity in melanoma patients.
• Conducted a multicenter prospective trial
• Evaluated 31-gene expression profile test in melanoma patients
• Assessed SLN positivity and recurrence-free survival (RFS) outcomes
• The gene expression profile test accurately predicted SLN positivity
• Patients who avoided SLNB had high recurrence-free survival (RFS)
• Identified a subset of low-risk melanoma patients